Aliskiren for geriatric lowering of systolic hypertension: A randomized controlled trial

Journal of Human Hypertension

Volumn 24, Issue 9, 2010, Pages 600-608

  Duprez, D A ^a   Munger, M A ^b   Botha, J ^c   Keefe, D L ^c   Charney, A N ^c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

aliskiren; blood pressure; combination therapy; direct renin inhibition; ramipril

Indexed keywords

ALISKIREN; AMLODIPINE; CREATININE; HYDROCHLOROTHIAZIDE; POTASSIUM; RAMIPRIL; SODIUM;

ADD ON THERAPY; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; UPPER RESPIRATORY TRACT INFECTION; UREA NITROGEN BLOOD LEVEL; URINARY TRACT INFECTION;

AGED; AMIDES; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; FEMALE; FUMARATES; HUMANS; HYPERTENSION; MALE; RAMIPRIL; RENIN; TREATMENT OUTCOME;

EID: 77955921291     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2009.107     Document Type: Article

References (34)

1. Duprez DA. Systolic hypertension in the elderly: addressing an unmet need. Am J Med 2008; 121: 179-184 e173.
2. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007; 49: 69-75.
3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
4. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187. (Pubitemid 46924065)
5. Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371: 1513-1518.
6. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.
7. Kostis JB, Davis BR, Cutler J, Grimm Jr RH, Berge KG, Cohen JD et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA 1997; 278: 212-216.
8. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3264.
9. Liu L, Wang JG, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens 1998; 16: 1823-1829.
10. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other bloodpressure- lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000; 356: 1955-1964.
11. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350: 757-764.
12. Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355: 865-872.
13. Kjeldsen SE, Dahlof B, Devereux RB, Julius S, Aurup P, Edelman J et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002; 288: 1491-1498.
14. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet 2006; 368: 1449-1456.
15. Turnbull F, Neal B, Pfeffer M, Kostis J, Algert C, Woodward M et al. Blood pressure-dependent and independent effects of agents that inhibit the renin- angiotensin system. J Hypertens 2007; 25: 951-958.
16. Brown MJ. Aliskiren. Circulation 2008; 118: 773-784.
17. Jordan J, Engeli S, Boye SW, Le Breton S, Keefe DL. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007; 49: 1047-1055.
18. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007; 370: 221-229.
19. Gianni M, Bosch J, Pogue J, Probstfield J, Dagenais G, Yusuf S et al. Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients. Eur Heart J 2007; 28: 1382-1388.
20. Verdecchia P, Calvo C, Mockel V, Keeling L, Satlin A. Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Blood Press 2007; 16: 381-391.
21. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-S266.
22. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: Blood pressure measurement in humans: A statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005; 45: 142-161. (Pubitemid 40066429)
23. Elliott WJ. Management of hypertension in the very elderly patient. Hypertension 2004; 44: 800-804.
24. Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D'Agostino RB et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 2002; 287: 1003-1010. (Pubitemid 34252058)
25. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887-1898.
26. Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Smith B, Weissbach N et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, doubleblind comparator trial with hydrochlorothiazide. Circulation 2009; 119: 417-425.
27. Vaidyanathan S, Reynolds C, Yeh CM, Bizot MN, Dieterich HA, Howard D et al. Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects. J Clin Pharmacol 2007; 47: 453-460.
28. Uresin Y, Taylor AA, Kilo C, Tschope D, Santonastaso M, Ibram G et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007; 8: 190-198.
29. Andersen K, Weinberger MH, Egan B, Constance CM, Ali MA, Jin J et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 2008; 26: 589-599.
30. Ho PM, Magid DJ, Shetterly SM, Olson KL, Peterson PN, Masoudi FA et al. Importance of therapy intensification and medication nonadherence for blood pressure control in patients with coronary disease. Arch Intern Med 2008; 168: 271-276.
31. Schmittdiel JA, Uratsu CS, Karter AJ, Heisler M, Subramanian U, Mangione CM et al. Why don't diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification. J Gen Intern Med 2008; 23: 588-594.
32. Van Tassell BW, Munger MA. Aliskiren for renin inhibition: a new class of antihypertensives. Ann Pharmacother 2007; 41: 456-464.
33. Weir MR, Bush C, Anderson DR, Zhang J, Keefe D, Satlin A. Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens 2007; 1: 264-277. (Pubitemid 47091546)
34. Gradman AH, Kad R. Renin inhibition in hypertension. J Am Coll Cardiol 2008; 51: 519-528.